TVGN — Tevogen Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1860871 ·
Last close
$7.25
Market Cap
$47.21M
52W High
$40.60
52W Low
$3.64
ADV30
7,437
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,662,376 | -5,761,940 | 4,727,741 | 1,082,155 | 13,616,501 |
| Mar 2026 | 0 | — | -5,400,920 | -5,446,255 | 4,921,005 | 692,305 | 14,763,163 |
| Dec 2025 | 0 | — | -4,610,201 | -4,677,580 | 4,382,994 | 552,372 | 12,617,720 |
| Sep 2025 | 0 | — | -5,729,431 | -5,726,812 | 4,493,669 | 1,037,094 | 12,317,565 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,754,283
Investing CF
$0
Financing CF
$10,536,095
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.86
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-145,106,804
Inventory
—
Receivables
$158,819
ST Investments
—
EBIT TTM
$-21,091,003
Pretax Income TTM
$-21,354,626
Interest Exp TTM
$228,751
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,140,515 | -26,275,432 | 4,382,994 | 12,617,720 | -8,234,726 | -12,328,577 |
| Dec 2024 | 0 | -53,564,488 | -13,727,380 | 3,461,675 | 10,135,680 | -6,674,005 | -11,998,730 |
| Dec 2023 | 0 | -8,843,025 | -60,477,680 | 5,505,503 | 99,934,400 | -94,428,897 | -8,171,118 |
| Dec 2022 | 0 | -953,083 | 4,408,361 | 357,138,356 | 15,057,704 | 342,080,652 | -215,395 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRML | Greenland Mines Ltd | $46.58M | $14.66 | — |
| TIL | Instil Bio, Inc. | $48.63M | $7.17 | — |
| BKHA | Black Hawk Acquisition Corp | $50.96M | $12.27 | — |
| MGX | Metagenomi Therapeutics, Inc. | $43.44M | $1.15 | — |
| ELOX | Eloxx Pharmaceuticals, Inc. | $51.65M | $15.03 | — |
News headlines (Yahoo Finance, 1h cache)
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
2026-07-29 12:00 · Yahoo
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
2026-07-14 02:15 · Yahoo
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
2026-05-28 16:30 · Yahoo
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
2026-05-21 16:15 · Yahoo
Letter to Shareholders from CEO Dr. Ryan Saadi
2026-05-18 16:15 · Yahoo
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
2026-05-12 15:45 · Yahoo
Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization
2026-05-05 01:24 · Yahoo
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
2026-04-27 15:50 · Yahoo
Tevogen Announces Formation of a Healthcare Services Initiative
2026-06-09 19:30 · Yahoo
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
2026-03-26 16:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.